Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Abstract Text:

OBJECTIVE: To evaluate the usefulness of intervention in drug interactions of antiretroviral drugs with coadministered agents by a clinical pharmacist in outpatient HIV-treatment. METHODS: The study design included two intervention arms (A and B), which were both preceded by a control observation period. In arm A, a complete list of the currently used drugs, extracted from pharmacy records was provided to the treating physician. In arm B the same list was provided but with a notification when a drug interaction was present and an advice how to handle this. The infectious disease specialist obtained the information before the patient's visit to the outpatient clinic (time point 0). Three months prior (time point -3) and 3 months after (time point +3) the intervention, pharmacy records were also screened for drug interactions. The number of drug interactions (total and per patient) was determined at the three different time points (-3, 0, +3). In addition, drug interactions encountered at time points -3 and 0 were checked for their presence at time points 0 and +3, respectively, for both intervention arms. RESULTS: Arms A and B included 115 and 105 patients, respectively. Patient characteristics of both intervention arms were similar at time point 0. The number of interactions and the number of patients with interactions were similar in both intervention arms at time point 0. There were 42 and 40 potential drug interactions in 30 and 24 patients in arms A and B, respectively. The reduction in the number of interactions per patient over time and after intervention was small but significant, and was equal in both intervention arms. The advice of the clinical pharmacist had thus no additional value. CONCLUSION: Both interventions were effective in reducing the number of drug interactions per patient. The advice of a clinical pharmacist was, however, redundant in the studied setting.

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Publishing Authors By Initials

For similar investigative techniques: clinical laboratory techniques: microbiological techniques: viral load research abstracts see: investigative techniques: clinical laboratory techniques: microbiological techniques: viral load research

PUBMED ID PMID:

MEDLINE DATE:

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of clinical pharmacy and therapeutics

VOLUME: 29

Page Numbers: 121-30

Journal Abbreviation: J Clin Pharm Ther

ISSN: 0269-4727

DAY: 28

MONTH: Apr

YEAR: 2004

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8704308

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Keywords Mesh Terms:

KEYWORDS: Viral Load

MESH TERMS: drug therapy

Chemical & Substance for Abstract: Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Information

Substance Name: Anti-HIV Agents

Registry Number: 0

Grant and Affiliation Information for Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.

AFFILIATION: Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands. apmod@slz.nl

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharm Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care Related Publications

• A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
• Amyloid Beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
• Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
• Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
• Didanosine, a new antiretroviral drug. A review.
• Dideoxynucleoside therapy for HIV infection.
• Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
• Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
• Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin(R) g
• Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
• Home-based chemotherapy confronts pharmacists with stability and compatibility problems.
• Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
• Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
• Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH(4) with biomarker potential in human plasma and serum.
• New cytotoxic drugs and targets in oncology.
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
• Platinum antitumour agents: a review of (bio)analysis.
• Prescription error resulting in valproic acid intoxication.
• Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
• Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
• Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
• Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS).
• The risks of handling cytotoxic drugs. I. Methods of testing exposure.
• The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.